Full Press Release Details
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver (EASL) International Liver Congress™ taking place in Milan, Italy from June 5-8, 2024.
Title: Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial
Late Breaker Abstract Number: LB27
Presenter: Michael Trauner, M.D., Chair of Gastroenterology and Hepatology, Department of Medicine III, Medical University Clinic, Vienna, Austria
Presentation Date and Time: Wednesday, June 5, 2024, 8:30 a.m. – Saturday, June 8, 2024, 5:00 p.m. CEST
Title: Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis
Abstract Number: 1627
Presenter: Johanna Schaub, Ph.D., Principal Scientist II, Translational Sciences, Pliant Therapeutics
Presentation Date and Time: Thursday, June 6, 2024, 8:30 a.m. – 6:00 p.m. CEST
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.